Citations

Clear

1055 citation(s) found for "Small, J C".

NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025
Riely, Gregory J. , Wood, Douglas E. , Aisner, Dara L. , Bauman, Jessica R. , Desai, Aakash , Dilling, Thomas J. , Durm, Gregory A. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Levy, Benjamin, Maldonado, Fabien , Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Owen, Dawn , Patel, Sandip Pravin , Riess, Jonathan W. , Mendez, Ana Lucia Ruano, Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yau, Edwin , Gregory, Kristina M., Hang, Lisa, Desai, Aakash P , Loo, Billy W. , Axtell, Andrea L. , Bharat, Ankit , Chang, Joe Y. , Dowell, Jonathan E. , Grotz, Travis E. , Juloori, Aditya , Lanuti, Michael D. , Lin, Jules , Lovly, Christine Marie , Owen, Dwight H , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 10, 2025 | Volume: 23 | Issue: 9 | Pages: 354-362

10.6004/jnccn.2025.0043 | PMID 40930154 Get It

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of NSCLC. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines, with a focus on systemic therapy options for the treatment of patients with nonmetastatic NSCLC and the corresponding molecular testing considerations.
An Orally Available Grafted Peptide Targeting Epidermal Growth Factor Receptor Dimers Reduces Non-Small Cell Lung Cancer Tumors in Mouse Models
Shrestha, Prajesh , Dahal, Achyut, Chowdhury, Arpan , Majumdar, Debajyoti, Gu, Xin , Johnson, William W., Zhang, Dachuan , Billadeau, Daniel D. , Jois, Seetharama D. , Zhang, Dachuan , Jois, Seetharama , Singh, Sitanshu S. , Prasasty, Vivitri Dewi , Johnson, William

Mayo Clinic

ACS Pharmacology & Translational Science | September 9, 2025 | Volume: 8 | Issue: 10 | Pages: 3531-3545

10.1021/acsptsci.5c00336 | PMID 41098571 Get It

ACR–ABS–ACNM–ARS–SIR–SNMMI Practice Parameter for Radioembolization of Liver Malignancies
Johnson, Thor, Spieler, Benjamin , Toskich, Beau , Wang, David S. , Russo, Suzanne , Sharma, Navesh , Wright, Chadwick , Farsad, Khashayar , Muzahir, Saima , Chundury, Anupama , Subramaniam, Rathan M. , Caplin, Drew M. , Schechter, Naomi R., Toskich, Beau B. , Hathout, Lara , Russo, Suzanne , Kim, Charles , Kappadath, Srinivas Cheenu , Parent, Ephraim E. , Sio, Terence T. , Mercier, Gustavo , Ghesani, Munir V. , Small, William

Mayo Clinic

American Journal of Clinical Oncology | September 3, 2025 | Volume: 49 | Issue: 1 | Pages: 10-24

10.1097/coc.0000000000001234 | PMID 40899409 Get It

Objectives: The practice parameter was revised collaboratively by the American College of Radiology (ACR), the American Brachytherapy Society (ABS), the American College of Nuclear Medicine (ACNM), the American Radium Society (ARS), the Society of Interventional Radiology (SIR), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). This document summarizes current evidence-based guidelines for the administration of Yttrium radioembolic therapy to the liver, including training requirements, evidence-based guidelines for administration, and safe practice for administration. Methods: This practice parameter was revised according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/ClinicalResources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters—Interventional and Cardiovascular Radiology of the ACR Commission on Interventional and Cardiovascular, Committee on Practice Parameters and Technical Standards—Nuclear Medicine and Molecular Imaging of the ACR Commission on Nuclear Medicine and Molecular Imaging and the Committee on Practice Parameters—Radiation Oncology of the ACR Commission on Radiation Oncology in collaboration with the ABS, the ACNM, the ARS, the SIR, and the SNMMI. Results: This review seeks not to be a comprehensive discussion of radiotherapy to the liver, but rather, seeks to provide a parameter for safe and effective therapy. We discuss the qualifications of physicians involved in this therapy, basic indications, contraindications, procedural work-up, safe-handling, and regulatory requirement for the administration of selective internal radiation therapy to patients that are likely to benefit. The goal of this document is not to define which patients are best treated by these therapies, as this is best determined for individual patients after multidisciplinary review. A consistent and evidence-based approach to therapy, however, would benefit all patients who are offered this therapy. This document seeks to provide a framework for current best practices for the administration of the 2 currently available radioembolization devices. Conclusions: As Yttrium-90 radiotherapy to the liver occupies a growing role in the treatment of primary and metastatic liver cancer, this review seeks to assist clinicians of all involved specialties to optimize the efficacy and safety of these procedures.
Progressive Increase in Small Intestinal Bacterial Overgrowth Risk Following COVID-19 Infection: A Global Population-Based Study
Song, Yilin , Koo, Thai Hau , Liu, Benjamin D. , Zhong, Linda L. D. , Hou, Xiaohua , Tu, Lei , Song, Gengqing , Tu, Lei , Song, Gengqing , Koo, Thai Hau , Bai, Tao

Mayo Clinic

Diseases | August 22, 2025 | Volume: 13 | Issue: 9 | Pages: 275

10.3390/diseases13090275 | PMID 41002711 Get It

Background/Objectives: Coronavirus disease 2019 (COVID-19) is associated with gastrointestinal (GI) symptoms. Small intestinal bacterial overgrowth (SIBO) is emerging as a significant GI sequela post-COVID-19 infection. This study aimed to evaluate the prevalence and incidence of SIBO post-COVID-19 infection across different age groups and to identify associated risk factors in a global cohort. Methods: A retrospective study utilized the TriNetX database and included adult patients (≥18 years) diagnosed with SIBO following COVID-19 infection (1 January 2022–30 May 2024). A propensity score matching (1:1) was used to adjust for demographics and SIBO risk factors. Kaplan–Meier survival analysis assessed the SIBO incidence within 12 months. Results: Among 1,660,092 COVID-19 patients and 42,322,017 controls, SIBO was diagnosed in 353 COVID-19 patients without hydrogen breath tests (BT) and 78 with BT, compared to 3368 controls without BT and 871 with BT. Age-specific analysis demonstrated a clear, progressive increase in the SIBO incidence, becoming distinctly significant by 6 months and highest at 12 months post-infection. The highest risks were noted in ages 60–69 (0.011% vs. 0.004%, OR 2.6, p = 0.0003) and 70–79 (0.011% vs. 0.005%, OR 2.0, p = 0.0004), with younger age groups (30–49 years) also showing significantly increased risks. The medication analysis revealed strong associations with chronic opioid, proton pump inhibitor, and antidiarrheal medication. Conclusions: COVID-19 significantly increased the risk of SIBO, particularly within the first 12 months post-infection, across various age groups and, notably, in association with certain chronic medications. Clinical vigilance and targeted management strategies are recommended to mitigate long-term GI consequences.
A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death–Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma
Kourelis, Taxiarchis , Ailawadhi, Sikander , Vogl, Dan T. , Gibson, Sarah E. , Sharik, Meaghen E. , Du, Megan T. , Ames, Tyler D. , Yim, Christina Y. , Baeck, Johan , Price, Matthew R. , Jimeno, J. , Chesi, Marta , Jimeno, Jose M , Bergsagel, P. Leif , Ailawadhi, Sikander , Gibson, Sarah E , Bergsagel, P. Leif

Mayo Clinic

Clinical Cancer Research | August 12, 2025 | Volume: 31 | Issue: 21 | Pages: 4518-4528

10.1158/1078-0432.ccr-24-2574 | PMID 40795066 Get It

Abstract Purpose: R,R-1,2 cyclohexanediamine-pyrophosphato-platinum(II) (PT-112) is a novel immunogenic cell death–inducing small molecule under phase II development in several cancer types. It inhibits ribosome biogenesis and causes organelle stresses, leading to selective immunogenic cell death in cancer cells. The possibility of PT-112’s pyrophosphate moiety driving high drug concentrations to bone sites of disease has led to an interest in PT-112’s use in multiple myeloma. In this study, we present findings from phase I and in vivo studies for PT-112 in relapsed or refractory multiple myeloma. Experimental Design: PT-112 biodistribution was analyzed in mice via laser ablation inductively coupled plasma mass spectrometry. The activity of PT-112 was assessed in de novo and transplantable Tg(Igkv3-5*-MYC)#Plbe (Vk*MYC) multiple myeloma mouse models as monotherapy or combination therapies. M-spike levels and survival were measured. A phase I dose escalation study of PT-112 monotherapy was conducted using a 3 + 3 design in patients with heavily pretreated relapsed or refractory multiple myeloma with exhausted available therapies. Results: In vivo biodistribution imaging revealed high concentrations in the bone, kidney, lung, skin, and liver. PT-112 was active in Vk*MYC multiple myeloma mouse models, both alone and in combination. Phase I data showed that PT-112 monotherapy was safe and well-tolerated, establishing a recommended phase II dose of 360 mg/m2 on days 1, 8, and 15 of a 28-day cycle. Confirmed responses and other signals of activity were observed. Conclusions: These results suggest a lack of cross-resistance with the standard of care and support the translational value of the Vk*MYC model system. Further clinical investigation of PT-112 is warranted in multiple myeloma.
Clinical Characteristics of Patients With Ulcerative Colitis and Small Intestinal Malignancy
Olson, Caroline G. , Picco, Michael F., Kinnucan, Jami , Picco, Michael, Olson, Caroline , Farraye, Francis A. , Hashash, Jana G.

Mayo Clinic

Crohn's & Colitis 360 | August 4, 2025 | Volume: 7 | Issue: 3 | Pages: No page available

10.1093/crocol/otaf041 | PMID 40761386 Get It

Abstract Background Prior studies have examined small intestinal dysplasia and cancer in Crohn’s disease; however, there is limited information on ulcerative colitis (UC). We describe characteristics of small intestinal dysplasia and cancer in patients with UC. In this study, we aimed to identify common characteristics between patients with UC that were diagnosed with small intestinal malignancy. Methods Electronic medical records were reviewed for 3 tertiary referral centers to identify patients with a diagnosis of UC and small intestinal dysplasia or cancer between 2010 and 2023. Data collection included demographics, family history of gastrointestinal malignancy, UC diagnosis date, duration and location of disease, prior UC medical treatment or surgery, diagnosis of primary sclerosing cholangitis (PSC), PSC-related complications, and details of cancer or dysplasia. Descriptive statistics were performed. Results Thirty-five patients (60% male, mean age of diagnosis 39.3 ± 21.5 years old) were identified with UC and subsequent small intestinal dysplasia or cancer. Most had pancolitis (74.3%) or pancolitis with backwash ileitis (8.57%). Half underwent surgery for their UC, and half of these had the cancer or dysplasia found at the time of surgery. Ileal dysplasia was found in 2 patients (5.71%), duodenal adenocarcinoma in 2 (5.71%), ileal adenocarcinoma 2 (5.71%), duodenal carcinoid in 4 (11.4%), ileal carcinoid in 24 (68.6%), other duodenal neuroendocrine tumor in 1 (2.86%). Primary sclerosing cholangitis was diagnosed in 5 patients (14%), and 3 required liver transplants. Conclusions Small intestinal dysplasia and cancer are rare in this population. Most patients with small intestinal cancer or dysplasia were male, Caucasian, and had a history of extensive colitis. Ileal carcinoid had the highest incidence. Gastroenterologists should be aware of this finding in patients with UC.
An Integrated Digital Microfluidic Device for the Extraction and Detection of Extracellular Vesicle‐Based Molecules
Lo, Ting‐Wen , Liu, Jing, Zhang, Yuqian , Kim, Yohan , Yao, Janet , Liu, Yuguang , Liu, Yuguang , Liu, Jing, Dong, Haidong , Lucien, Fabrice

Mayo Clinic

Small | July 31, 2025 | Volume: 21 | Issue: 38 | Pages: No page available

10.1002/smll.202504335 | PMID 40739977 Get It

Abstract Extracellular vesicles (EV) are phospholipid‐encapsulated nanoparticles secreted by cells into their surrounding environment. EVs can transfer a variety of biomolecules that mediate intercellular communication and play a key role in physiological and pathological processes. Therefore, EVs are emerging as new biomarkers for diseases, therapeutic targets, and drug delivery vehicles. The isolation and detection of EVs requires time‐consuming and labor‐intensive processes, first to extract EVs from biological and physiological fluids and then to detect EV‐associated molecules with high sensitivity. The methodologies and instruments commonly used for EV analysis are not widely accessible outside of dedicated research laboratories, creating practical barriers for the study of EV‐associated molecules in biology research and clinical applications. To bridge this gap, we developed a proof‐of‐concept digital microfluidic device that can automatedly extract EVs from 20 µL of culture and human plasma samples within 25 min and detect EV‐bound proteins (e.g PD‐L1) on‐chip using an electrochemical sensor. This work serves as a framework for the development of streamlined EV analysis in both research and diagnostics.
Midlife Retinal Microvascular Signs and Late-Life Neuroimaging Features of Cerebral Small Vessel Disease in the ARIC Study
Jiang, Kening , Power, Melinda C. , Bandeen‐Roche, Karen , Griswold, Michael , Albert, Marilyn , Knopman, David S. , Mosley, Thomas H. , Walker, Keenan A. , Sharrett, A. Richey, Egle, Marco , Mosley, Thomas H. , Knopman, David S. , Griswold, Michael , Albert, Marilyn S. , Gottesman, Rebecca F , Egle, Marco , Deal, Jennifer A , Walker, Keenan A , Gottesman, Rebecca F. , Deal, Jennifer A.

Mayo Clinic

Neurology | July 25, 2025 | Volume: 105 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000213919 | PMID 40712116 Get It

Executive Summary of the American Radium Society Appropriate Use Criteria for the Management of Peritoneal Carcinomatosis From Different Tumor Origins: Systematic Review and Guidelines
Carcinomatosis, Expert Panel Management of Peritoneal, Kennedy, Timothy J., Singh, Sareena , Abood, Gerard, Anker, Christopher J. , Akselrod, Dmitriy , Hallemeier, Christopher L. , Lee, Percy , Newman, Neil B., Sharma, Navesh , Williams, Vonetta M. , Russo, Suzanne , Akselrod, Dmitriy , Hallemeier, Christopher Leigh , Small, William , Russo, Suzanne , Carcinomatosis, Expert Panel Management of Peritoneal, Christenson, Eric, Jethwa, Krishan R. , Kim, Ed, Miller, Eric D. , Newman, Neil B., Selfridge, Jennifer Eva , Tchelebi, Leila T.

Mayo Clinic

Cancer Medicine | July 22, 2025 | Volume: 14 | Issue: 14 | Pages: No page available

10.1002/cam4.71043 | PMID 40693544 Get It

ABSTRACT Background Multimodality therapy incorporating a combination of cytoreductive surgery (CRS), intraperitoneal (IP) and systemic therapy continues to evolve for peritoneal carcinomatosis (PC) However, treatment and outcomes vary depending on tumor of origin. Aims To develop Appropriate Use Criteria (AUC) guidelines to facilitate treatment decision‐making for patients with PC based on available evidence. Materials and Methods The American Radium Society (ARS) multidisciplinary expert panel performed a comprehensive systematic review. Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) methodology was used. These studies were used to inform the expert panel, which then rated the appropriateness of various treatments in seven representative clinical scenarios through a well‐established modified Delphi consensus methodology. Results Treatment of PC is often treated with a combination of CRS and IP ± systemic chemotherapy but specific recommendations exist for different tumor types and outcomes vary. Discussion Treatment of PC is complex and varies depending on origin of primary tumor and extent of disease. These AUC assist in patient and treatment selection for different clinical scenarios. Conclusion A summary of recommendations is outlined to guide practitioners on the management of PC from different tumor origins.